

FORM 1-139 (Modified)
(REV. 1-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

DEX-0184

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/806311

INTERNATIONAL APPLICATION NO.
PCT/US99/22725INTERNATIONAL FILING DATE
30 September 1999PRIORITY DATE CLAIMED
2 October 1998

TITLE OF INVENTION

A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Gastrointestinal Cancers

APPLICANT(S) FOR DO/EO/US

MACINA, Roberto A.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). - **unexecuted**
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

- 1) Courtesy copy of International Application
- 2) Written Opinion
- 3) Return post card

"Express Mail" Label No. **EL846058763US**
Date of Deposit **March 29, 2001**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

| | | | | | |
|--|--|--|--|---|--|
| U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) 09/806311 | | INTERNATIONAL APPLICATION NO. PCT/US99/22725 | | ATTORNEY'S DOCKET NUMBER DEX-0184 | |
|--|--|--|--|---|--|


| | | | | | |
|--|--------------|--------------|-----------|----------------------------------|----|
| 21. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : | | | | CALCULATIONS PTO USE ONLY | |
| <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00 | | | | | |
| <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00 | | | | | |
| <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00 | | | | | |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00 | | | | | |
| <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 | | | | | |
| ENTER APPROPRIATE BASIC FEE AMOUNT = | | | | \$860.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)). | | | | \$0.00 | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | | |
| Total claims | 10 - 20 = | 0 | x \$18.00 | \$0.00 | |
| Independent claims | 6 - 3 = | 3 | x \$80.00 | \$240.00 | |
| Multiple Dependent Claims (check if applicable). <input type="checkbox"/> | | | | \$0.00 | |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$1,100.00 | |
| Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/> | | | | \$0.00 | |
| SUBTOTAL = | | | | \$1,100.00 | |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). | | | | \$0.00 | |
| TOTAL NATIONAL FEE = | | | | \$1,100.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/> | | | | \$0.00 | |
| TOTAL FEES ENCLOSED = | | | | \$1,100.00 | |
| | | | | Amount to be: refunded | \$ |
| | | | | charged | \$ |

☐ A check in the amount of _____ to cover the above fees is enclosed.
☒ **Credit Card Payment form for \$1,100.00**
☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.


☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **50-1619** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

| | |
|--|---|
| Jane Massey Licata, Reg. No. 32,257 Kathleen A. Tyrrell, Reg. No. 38,350 Licata & Tyrrell P.C. 66 E. Main Street Marlton, New Jersey 08053 Telephone: (856) 810-1515 Facsimile: (856) 810-1454 | <div style="text-align: center;">  SIGNATURE </div> <hr/> Jane Massey Licata NAME |
| | <hr/> 32,257 REGISTRATION NUMBER |
| | <hr/> March 29, 2001 DATE |

30 APR 2002

2002 

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|----------------------|--|
| Attorney Docket No.: | DEX-0184 |
| Inventors: | Roberto A. Macina |
| Serial No.: | 09/806,311 |
| Filing Date: | Not yet assigned |
| Examiner: | Not yet assigned |
| Group Art Unit: | Not yet assigned |
| Title: | A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Gastrointestinal Cancers |

"Express Mail" Label No. **EV1043646895US**
Date of Deposit - **April 30, 2002**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327 Arlington, VA 22202

By Kathleen A. Tyrrell
Typed Name: Kathleen A. Tyrrell

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202


Sir:

AMENDMENT

In response to the "Notification of Defective Response" dated **April 3, 2002**, a response to which is due **May 3, 2002**, it is requested that the paper copy and CRF copy of the Sequence Listing pending in the instant application be replaced with the amended paper copy and CRF copy of the Sequence Listing provided herewith.

Amendments to the Sequence Listing were made to conform with the current Sequence Listing Rules. No new matter has been added by these amendments.

Respectfully submitted,



Kathleen A. Tyrrell
Registration No. 38,350

Date: April 30, 2002

LICATA & TYRRELL P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Rec'd PCT/PTO

30 APR 2002

RECEIVED 30 APR 2002

#8

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: DEX-0184
Inventors: Roberto A. Macina
Serial No.: 09/806,311
Filing Date: Not yet assigned
Examiner: Not yet assigned
Group Art Unit: Not yet assigned
Title: A Novel Method of Diagnosing,
Monitoring, Staging, Imaging and
Treating Gastrointestinal Cancers

"Express Mail" Label No. EV1043646895US
Date of Deposit - April 30, 2002

I hereby certify that this paper is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the U.S. Patent and
Trademark Office, Box Sequence, P.O. Box 2327 Arlington, VA 22202

By Kathleen A. Tyrén
Typed Name: Kathleen A. Tyrén

U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

Sir:

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE
WITH 37 CFR §§ 1.821 THROUGH 1.825


- () I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
- () I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.

48 50 51 52 53 54 55 56 57 58 59 60

Rec'd PCT/PTO 30 APR 2002

- () I hereby state that the submission filed in accordance with **37 CFR §1.821(h)** does not include new matter or go beyond the disclosure in the international application as filed.
- (XX) I hereby state that the amendments, made in accordance with **37 CFR §1.825(a)**, included in the substitute sheet(s) of the Sequence Listing were made to conform with the current Sequence Listing rules. I hereby state that the substitute sheet(s) of the Sequence Listing does not include new matter.
- (XX) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended Sequence Listing.
- () I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, contains identical data to that originally filed.

Respectfully submitted,




Kathleen A. Tyrrell
Registration No. 38,350

Date: April 30, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515



PCT09

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/806,311B

DATE: 07/22/2002

TIME: 14:06:20

Input Set : A:\PTO.DC.txt

Output Set: N:\CRF3\07222002\I806311B.raw

3 <110> APPLICANT: Macina, Roberto A.
5 <120> TITLE OF INVENTION: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING
AND TREATING
6 GASTROINTESTINAL CANCERS
8 <130> FILE REFERENCE: DEX-0184
C--> 10 <140> CURRENT APPLICATION NUMBER: US/09/806,311B
C--> 10 <141> CURRENT FILING DATE: 2002-04-30
10 <150> PRIOR APPLICATION NUMBER: PCT/US99/22725
11 <151> PRIOR FILING DATE: 1999-09-30
13 <150> PRIOR APPLICATION NUMBER: 60/102,879
14 <151> PRIOR FILING DATE: 1998-10-02
16 <160> NUMBER OF SEQ ID NOS: 2
18 <170> SOFTWARE: PatentIn version 3.1
20 <210> SEQ ID NO: 1
21 <211> LENGTH: 1255
22 <212> TYPE: DNA
23 <213> ORGANISM: Homo sapien
25 <220> FEATURE:
26 <221> NAME/KEY: misc_feature
27 <222> LOCATION: (1224)..(1224)
28 <223> OTHER INFORMATION: n= a, c, g or t
31 <220> FEATURE:
32 <221> NAME/KEY: misc_feature
33 <222> LOCATION: (1234)..(1234)
34 <223> OTHER INFORMATION: n= a, c, g or t
37 <220> FEATURE:
38 <221> NAME/KEY: misc_feature
39 <222> LOCATION: (1238)..(1238)
40 <223> OTHER INFORMATION: n= a, c, g or t
43 <220> FEATURE:
44 <221> NAME/KEY: misc_feature
45 <222> LOCATION: (1247)..(1248)
46 <223> OTHER INFORMATION: n= a, c, g or t
49 <400> SEQUENCE: 1
50 aagatataaa agctccagaa acgttgactg ggaccactgg aggcacgagg aaggcagggg 60
52 cccttagagt cttggttgcc aaacagattt gcagatcaag gagaacccag gagtttcaaa 120
54 gaagcgctag taaggtctct gagatccttg cactagctac atcctcaggg taggaggaag 180
56 atggcttcca gaagcatgag gctgctccta ttgctgagct gcctggccaa aacaggagtc 240
58 ctgggtgata tcatcatgag acccagctgt gctcctggat ggttttacca caagtccaat 300
60 tgcctatggtt acttcaggaa gctgaggaac ttggtctgat ccgagctcga gtgtcagtct 360
62 tacggaaacg gagcccaact ggcattctatc ctgagtttaa aggaagccag caccatagca 420
64 gactacataa gtggctatca gagaagccag ccgatatgga ttggcctgca cgaccacag 480
66 aagaggcagc agtggcagtg gattgatggg gccatgtatc tgtacagatc ctgggtctggc 540
68 aagtccatgg gtgggaacaa gcactgtgct gagatgagct ccaataacaa ctttttaact 600

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/806,311B

DATE: 07/22/2002

TIME: 14:06:20

Input Set : A:\PTO.DC.txt

Output Set: N:\CRF3\07222002\I806311B.raw

```

70 tggagcagca acgaatgcaa caagcgccaa cacttcctgt gcaagtaccg accatagagc 660
72 aagaatcaag attctgctaa ctccctgcaca gccccgtcct ctccctttct gctagcctgg 720
74 ctaaatctgc tcattatttc agaggggaaa cctagcaaac taagagtgat aagggcccta 780
76 ctacactggc ttttttaggc ttagagacag aaacttttagc attggcccag tagtggttc 840
78 tagctctaaa tgtttgcccc gccatccctt tccacagtat ccttcttccc tctcccccctg 900
80 tctctggtg tctcgagcag tctagaagag tgcattctcca gcctatgaaa cagctgggtc 960
82 tttggccata agaagtaaag atttgaagac agaaggaaga aactcaggag taagcttcta 1020
84 gaccccttca gcttctacac ccttctgccc tctctccatt gcctgcaccc caccaccagcc 1080
86 actcaactcc tgcttggttt tcttttgccc ataggaaggt ttaccagtag aatccttgct 1140
88 aggttgatgt gggccataca ttcctttaat aaaccattgt gtacatgaag aaaaaaaaaa 1200
W--> 90 aaaaaaaaaa aaaggggggg ccgnttcaag gggntccnaa gtttganntg acggg 1255
93 <210> SEQ ID NO: 2
94 <211> LENGTH: 153
95 <212> TYPE: PRT
96 <213> ORGANISM: Homo sapien
98 <400> SEQUENCE: 2
100 Met Arg Leu Leu Leu Leu Ser Cys Leu Ala Lys Thr Gly Val Leu
101 1 5 10 15
104 Gly Asp Ile Ile Met Arg Pro Ser Cys Ala Pro Gly Trp Phe Tyr His
105 20 25 30
108 Lys Ser Asn Cys Tyr Gly Tyr Phe Arg Lys Leu Arg Asn Trp Ser Asp
109 35 40 45
112 Ala Glu Leu Glu Cys Gln Ser Tyr Gly Asn Gly Ala His Leu Ala Ser
113 50 55 60
116 Ile Leu Ser Leu Lys Glu Ala Ser Thr Ile Ala Glu Tyr Ile Ser Gly
117 65 70 75 80
120 Tyr Gln Arg Ser Gln Pro Ile Trp Ile Gly Leu His Asp Pro Gln Lys
121 85 90 95
124 Arg Gln Gln Trp Gln Trp Ile Asp Gly Ala Met Tyr Leu Tyr Arg Ser
125 100 105 110
128 Trp Ser Gly Lys Ser Met Gly Gly Asn Lys His Cys Ala Glu Met Ser
129 115 120 125
132 Ser Asn Asn Asn Phe Leu Thr Trp Ser Ser Asn Glu Cys Asn Lys Arg
133 130 135 140
136 Gln His Phe Leu Cys Lys Tyr Arg Pro
137 145 150

```


RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/806,311B

DATE: 07/22/2002
TIME: 14:06:21

Input Set : A:\PTO.DC.txt
Output Set: N:\CRF3\07222002\I806311B.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; N Pos. 1224,1234,1238,1247,1248

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/806,311B

DATE: 07/22/2002

TIME: 14:06:21

Input Set : A:\PTO.DC.txt

Output Set: N:\CRF3\07222002\I806311B.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:90 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:1200



Does Not Comply
Corrected Diskette Needed

TIME: 15:39:26

Output Set: N:\CRF3\07162002\I806311B.raw

ERRORED SEQUENCES

E--> 143 (3) - delete
E--> 149 (3)

VERIFICATION SUMMARY

DATE: 07/16/2002

PATENT APPLICATION: US/09/806,311B

TIME: 15:39:27

Input Set : A:\PTO.VSK.txt

Output Set: N:\CRF3\07162002\I806311B.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:90 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:1200
L:143 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:2
M:332 Repeated in SeqNo=2

Rec'd PCT/PTO 30 APR 2002

09606311-0961401

#8

1

SEQUENCE LISTING

<110> Macina, Roberto A.

<120> A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND
TREATING GASTROINTESTINAL CANCERS

<130> DEX-0184

<150> PCT/US99/22725

<151> 1999-09-30

<150> 60/102,879

<151> 1998-10-02

<160> 2

<170> PatentIn version 3.1

<210> 1

<211> 1255

<212> DNA

<213> Homo sapien

<220>

<221> misc_feature

<222> (1224)..(1224)

<223> n= a, c, g or t

<220>

<221> misc_feature

<222> (1234)..(1234)

<223> n= a, c, g or t

<220>

<221> misc_feature

<222> (1238)..(1238)

<223> n= a, c, g or t

<220>

<221> misc_feature

<222> (1247)..(1248)

<223> n= a, c, g or t

<400> 1

aagatataaa agctccagaa acgttgactg ggaccactgg aggcacgagg aaggcagggg 60

cccttagagt cttggttgcc aaacagattt gcagatcaag gagaaccag gagtttcaaa 120

gaagcgctag taaggtctct gagatccttg cactagctac atcctcaggg taggaggaag 180

atggcttcca gaagcatgcg gctgctcta ttgctgagct gcctggccaa aacaggagtc 240

ctgggtgata tcatcatgag acccagctgt gtcctgggat gggtttacca caagtccaat 300

tgctatgggt acttcaggaa gctgaggaac tggctctgatg ccgagctcga gtgtcagtct 360

2

tacggaaacg gageccacct ggcatctatc ctgagtttaa aggaagccag caccatagca 420
gagtacataa gtggctatca gagaagccag ccgatatgga ttggcctgca cgacccacag 480
aagaggcagc agtggcagtg gattgatggg gccatgtatc tgtacagatc ctgggtctggc 540
aagtccatgg gtgggaacaa gcactgtgct gagatgagct ccaataacaa ctttttaact 600
tggagcagca acgaatgcaa caagcgccaa cacttctgtg gcaagtaccg accatagagc 660
aagaatcaag attctgctaa ctctgcaca gcccgcctct cttcttttct gctagcctgg 720
ctaaatctgc tcattatttc agaggggaaa cctagcaaac taagagtgat aagggcccta 780
ctacactggc ttttttaggc ttagagacag aaacttttagc attggcccag tagtggcttc 840
tagctctaaa tgtttgcccc gccatccctt tccacagtat ccttcttccc tctcccctg 900
tctctggctg tctcgagcag tctagaagag tgcattccca gcctatgaaa cagctgggtc 960
tttggccata agaagtaaag atttgaagac agaaggaaga aactcaggag taagcttcta 1020
gaccccttca gcttctacac ccttctgccc tctctccatt gcctgcaccc caccacagcc 1080
actcaactcc tgcttgcttt tcttttgccc ataggaaggt ttaccagtag aatccttgct 1140
aggttgatgt gggccataca ttcctttaat aaaccattgt gtacatgaag aaaaaaaaaa 1200
aaaaaaaaaa aaaggggggg ccgnttcaag gggntccnaa gtttganntg acggg 1255

<210> 2
<211> 153
<212> PRT
<213> Homo sapien

<400> 2

Met Arg Leu Leu Leu Leu Ser Cys Leu Ala Lys Thr Gly Val Leu
1 5 10 15

Gly Asp Ile Ile Met Arg Pro Ser Cys Ala Pro Gly Trp Phe Tyr His
20 25 30

Lys Ser Asn Cys Tyr Gly Tyr Phe Arg Lys Leu Arg Asn Trp Ser Asp
35 40 45

Ala Glu Leu Glu Cys Gln Ser Tyr Gly Asn Gly Ala His Leu Ala Ser
50 55 60

Ile Leu Ser Leu Lys Glu Ala Ser Thr Ile Ala Glu Tyr Ile Ser Gly
65 70 75 80

Tyr Gln Arg Ser Gln Pro Ile Trp Ile Gly Leu His Asp Pro Gln Lys
85 90 95

3

Arg Gln Gln Trp Gln Trp Ile Asp Gly Ala Met Tyr Leu Tyr Arg Ser
100 105 110

Trp Ser Gly Lys Ser Met Gly Gly Asn Lys His Cys Ala Glu Met Ser
115 120 125

Ser Asn Asn Asn Phe Leu Thr Trp Ser Ser Asn Glu Cys Asn Lys Arg
130 135 140

Gln His Phe Leu Cys Lys Tyr Arg Pro
145 150

3

A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING,
IMAGING AND TREATING GASTROINTESTINAL CANCERS

FIELD OF THE INVENTION

This invention relates, in part, to newly developed
5 assays for detecting, diagnosing, monitoring, staging
prognosticating, imaging and treating cancers, particularly
gastrointestinal cancers including cancer of the stomach,
small intestine and colon.

BACKGROUND OF THE INVENTION

10 Cancer of the colon is the second most frequently
diagnosed malignancy in the United States, as well as the
second most common cause of cancer death. Colon cancer is
a highly treatable and often curable disease when localized
to the bowel. Surgery is the primary treatment and results
15 in cure in approximately 50% of patients. However,
recurrence and metastases following surgery is a major
problem and often is the ultimate cause of death.

Due to its proximity, cancer of the colon often
metastasizes to the small intestine. The prognosis of the
20 cancer spreading to the small intestine is related to the
degree of penetration of the tumor through the bowel wall
and the presence or absence of nodal involvement. These
two characteristics form the basis for all staging systems
developed for colon cancer. Various characteristics also
25 assist in prognosticating colon cancer and its spread to
the small intestines. For example, bowel obstruction and
bowel perforation are indicators of poor prognosis.
Elevated pretreatment serum levels of carcinoembryonic
antigen (CEA) and of carbohydrate antigen 19-9 (CA 19-9)
30 also have a negative prognostic significance. However, age
greater than 70 years at presentation is not a
contraindication to standard therapies; acceptable

- 2 -

morbidity and mortality, as well as long-term survival, are achieved in this patient population.

Cancer cells can also originate in the small intestine. However, this is a much rarer type of cancer.

5 Symptoms of cancer of the small intestine typically include pain or cramps in the middle of the abdomen, weight loss without dieting, a lump in the abdomen or blood in the stool.

Cancer of the stomach, also referred to as gastric
10 cancer, also frequently metastasizes to the small intestine due to its proximity. This cancer is often difficult to diagnose in early stages and can be in the stomach for a long time, growing to a large size before symptoms arise. In the early stages of cancer of the stomach, an individual
15 may experience indigestion and stomach discomfort, a bloated feeling after eating, mild nausea, loss of appetite or heartburn. In more advanced stages of stomach cancer, there may be blood in the stool, vomiting, weight loss or more severe pain.

20 Because of the frequency of these types of cancer (approximately 160,000 new cases of colon and rectal cancer per year alone), the identification of high-risk groups, the demonstrated slow growth of primary lesions and the better survival of early-stage lesions, screening for
25 gastrointestinal cancers should be a part of routine care for all adults starting at age 50, especially those with first-degree relatives with colorectal cancer.

Procedures used for detecting, diagnosing, monitoring, staging, and prognosticating cancer of the
30 colon, small intestine or stomach are of critical importance to the outcome of the patient. Patients diagnosed with early stage cancer generally have a much greater five-year survival rate as compared to the survival rate for patients diagnosed with distant metastasized
35 cancers. New diagnostic methods which are more sensitive

- 3 -

and specific for detecting early cancer of the stomach, small intestine and colon are clearly needed.

Patients with gastrointestinal cancers are closely monitored following initial therapy and during adjuvant
5 therapy to determine response to therapy and to detect persistent or recurrent disease of metastasis. There is clearly a need for a cancer marker which is more sensitive and specific in detecting recurrence of these types of cancer.

10 Another important step in managing gastrointestinal cancers is to determine the stage of the patient's disease. Stage determination has potential prognostic value and provides criteria for designing optimal therapy. Generally, pathological staging of cancer is preferable
15 over clinical staging because the former gives a more accurate prognosis. However, clinical staging would be preferred were it at least as accurate as pathological staging because it does not depend on an invasive procedure to obtain tissue for pathological evaluation. Staging of
20 gastrointestinal cancers would be improved by identifying new markers in cells, tissues, or bodily fluids which could differentiate between different stages of invasion.

Thirteen colon specific genes and naturally occurring variants thereof, referred to as CSG1-13, are disclosed in
25 U.S. Patent 5,733,748 and WO 96/39541 for use as diagnostic markers in colon cancer. Some of these genes and polypeptides encoded thereby are also taught to be useful in determining if the colon cancer has metastasized.

U.S. Patent 5,861,494, which issued January 19, 1999,
30 also discloses a gene and polypeptide encoded thereby for use as a diagnostic marker for colon cancer and as an agent for determining if the colon cancer has metastasized. This gene and the polypeptide encoded thereby are similar in sequence to the cancer specific gene referred to herein as
35 CC2.

- 4 -

It has now been found that CC2 is a useful diagnostic and metastatic marker not only for colon cancer but also for cancer of the stomach and small intestine. Thus, in the present invention, methods are provided for detecting, 5 diagnosing, monitoring, staging, prognosticating, imaging and treating gastrointestinal cancers including cancer of the stomach, small intestine and colon via the cancer specific gene referred to herein as CC2. CC2 refers, among other things, to native protein expressed by the gene 10 comprising the polynucleotide sequence of SEQ ID NO:1. The amino acid sequence of a polypeptide encoded by SEQ ID NO:1 is depicted herein as SEQ ID NO:2. In the alternative, what is meant by CC2 as used herein, means the native mRNA encoded by the gene comprising the polynucleotide sequence 15 of SEQ ID NO:1 or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should 20 be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will 25 become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

SUMMARY OF THE INVENTION

Toward these ends, and others, it is an object of the 30 present invention to provide a method for diagnosing the presence of a gastrointestinal cancer by analyzing for changes in levels of CC2 in cells, tissues or bodily fluids compared with levels of CC2 in preferably the same cells, tissues, or bodily fluid type of a normal human control,

- 5 -

wherein a change in levels of CC2 in the patient versus the normal human control is associated with a gastrointestinal cancer.

Further provided is a method of diagnosing metastatic cancer in a patient having a gastrointestinal cancer which is not known to have metastasized by identifying a human patient suspected of having a gastrointestinal cancer that has metastasized; analyzing a sample of cells, tissues, or bodily fluid from such patient for CC2; comparing the CC2 levels in such cells, tissues, or bodily fluid with levels of CC2 in preferably the same cells, tissues, or bodily fluid type of a normal human control, wherein an increase in CC2 levels in the patient versus the normal human control is associated with a gastrointestinal cancer which has metastasized.

Also provided by the invention is a method of staging a gastrointestinal cancer in a human which has such cancer by identifying a human patient having such cancer; analyzing a sample of cells, tissues, or bodily fluid from such patient for CC2; comparing CC2 levels in such cells, tissues, or bodily fluid with levels of CC2 in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CC2 levels in the patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CC2 is associated with a cancer which is regressing or in remission.

Further provided is a method of monitoring a gastrointestinal cancer in a human having such cancer for the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues, or bodily fluid from such patient for CC2; comparing the CC2 levels in such cells, tissue, or bodily fluid with levels of CC2 in preferably the same cells,

- 6 -

tissues, or bodily fluid type of a normal human control sample, wherein an increase in CC2 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

5 Further provided is a method of monitoring the change in stage of a gastrointestinal cancer in a human having such cancer by looking at levels of CC2 in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample
10 of cells, tissues, or bodily fluid from such patient for CC2; comparing the CC2 levels in such cells, tissue, or bodily fluid with levels of CC2 in preferably the same cells, tissues, or bodily fluid type of a normal human control sample, wherein an increase in CC2 levels in the
15 patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CC2 is associated with a cancer which is regressing or in remission.

Further provided are antibodies targeted against CC2
20 or fragments of such antibodies which can be used to detect or image localization of CC2 in a patient for the purpose of detecting or diagnosing a disease or condition. Such antibodies can be polyclonal, monoclonal, or omniconal or prepared by molecular biology techniques. The term
25 "antibody", as used herein and throughout the instant specification is also meant to include aptamers and single-stranded oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art. Antibodies can be
30 labeled with a variety of detectable labels including, but not limited to, radioisotopes and paramagnetic metals. These antibodies or fragments thereof can also be used as therapeutic agents in the treatment of diseases characterized by expression of CC2. In therapeutic
35 applications, the antibody can be used without or with

- 7 -

derivatization to a cytotoxic agent such as a radioisotope, enzyme, toxin, drug or a prodrug.

Other objects, features, advantages and aspects of the present invention will become apparent to those of skill in the art from the following description. It should be understood, however, that the following description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only. Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following description and from reading the other parts of the present disclosure.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to diagnostic assays and methods, both quantitative and qualitative for detecting, diagnosing, monitoring, staging and prognosticating cancers by comparing levels of CC2 with those of CC2 in a normal human control. What is meant by levels of CC2 as used herein, means levels of the native protein expressed by the gene comprising the polynucleotide sequence of SEQ ID NO:1. The amino acid sequence of a polypeptide encoded by SEQ ID NO:1 is depicted herein as SEQ ID NO:2. In the alternative, what is meant by levels of CC2 as used herein, means levels of the native mRNA encoded by the gene comprising the polynucleotide sequence of SEQ ID NO:1 or levels of the gene comprising the polynucleotide sequence of SEQ ID NO:1. Such levels are preferably measured in at least one of cells, tissues and/or bodily fluids, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for diagnosing overexpression of CC2 protein compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of cancers,

- 8 -

and in particular gastrointestinal cancers. By gastrointestinal cancers it is meant to include stomach cancer, cancer of the small intestine, and colon cancer.

All the methods of the present invention may optionally include measuring levels of other cancer markers as well as CC2. Other cancer markers, in addition to CC2, useful in the present invention will depend on the cancer being tested and are known to those of skill in the art.

Diagnostic Assays

10 The present invention provides methods for diagnosing the presence of a gastrointestinal cancer by analyzing for changes in levels of CC2 in cells, tissues or bodily fluids compared with levels of CC2 in cells, tissues or bodily fluids of preferably the same type from a normal human
15 control, wherein a change in levels of CC2 in the patient versus the normal human control is associated with the presence of a gastrointestinal cancer.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result
20 indicating the patient being tested has cancer is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CC2, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a
25 normal human control.

The present invention also provides a method of diagnosing the onset of metastatic gastrointestinal cancers in a patient having a gastrointestinal cancer which has not yet metastasized. In the method of the present invention,
30 a human cancer patient suspected of having a gastrointestinal cancer which may have metastasized (but which was not previously known to have metastasized) is identified. This is accomplished by a variety of means known to those of skill in the art.

- 9 -

In the present invention, determining the presence of CC2 levels in cells, tissues or bodily fluid, is particularly useful for discriminating between gastrointestinal cancers which have not metastasized and gastrointestinal cancers which have metastasized. Existing techniques have difficulty discriminating between gastrointestinal cancers which have metastasized and gastrointestinal cancers which have not metastasized. However, proper treatment selection is often dependent upon such knowledge.

In the present invention, the cancer marker level measured in cells, tissues or bodily fluid of a human patient is CC2. The measured CC2 level in the human patient is compared with levels of CC2 in preferably the same cells, tissue or bodily fluid type of a normal human control. That is, if the cancer marker being observed is CC2 in serum, this level is preferably compared with the level of CC2 in serum of a normal human control. An increase in the CC2 in the patient versus the normal human control is associated with a gastrointestinal cancer which has metastasized.

Without limiting the instant invention, typically, for a quantitative diagnostic assay a positive result indicating the cancer in the patient being tested or monitored has metastasized is one in which cells, tissues or bodily fluid levels of the cancer marker, such as CC2, are at least two times higher, and most preferably are at least five times higher, than in preferably the same cells, tissues or bodily fluid of a normal patient.

Normal human control as used herein includes a human patient without cancer and/or non cancerous samples from the patient; in the methods for diagnosing or monitoring for metastasis, normal human control may preferably also include samples from a human patient that is determined by

- 10 -

reliable methods to have a gastrointestinal cancer which has not metastasized.

Staging

The invention also provides a method of staging
5 gastrointestinal cancers in a human patient. The method comprises identifying a human patient having such cancer and analyzing a sample of cells, tissues or bodily fluid from such human patient for CC2. In this method CC2 levels in such cells, tissues or bodily fluid are then compared
10 with levels of CC2 in preferably the same cells, tissues or bodily fluid type of a normal human control sample, wherein an increase in CC2 levels in the human patient versus the normal human control is associated with a cancer which is progressing and a decrease in the levels of CC2 is
15 associated with a cancer which is regressing or in remission.

Monitoring

Further provided is a method of monitoring
gastrointestinal cancers in a human having such cancer for
20 the onset of metastasis. The method comprises identifying a human patient having such cancer that is not known to have metastasized; periodically analyzing a sample of cells, tissues or bodily fluid from such human patient for CC2; comparing the CC2 levels in such cells, tissues or
25 bodily fluid with levels of CC2 in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CC2 levels in the human patient versus the normal human control is associated with a cancer which has metastasized.

30 Further provided by this invention is a method of monitoring the change in stage of gastrointestinal cancers in a human having such cancer. The method comprises identifying a human patient having such cancer; periodically analyzing a sample of cells, tissues or bodily
35 fluid from such human patient for CC2; and comparing the

- 11 -

CC2 levels in such cells, tissues or bodily fluid with levels of CC2 in preferably the same cells, tissues or bodily fluid type of a normal human control, wherein an increase in CC2 levels in the human patient versus the normal human control is associated with a cancer which is progressing in stage and a decrease in the levels of CC2 is associated with a cancer which is regressing in stage or in remission.

Monitoring such patient for onset of metastasis is periodic and preferably done on a quarterly basis. However, this may be more or less frequent depending on the cancer, the particular patient, and the stage of the cancer.

Assay Techniques

Assay techniques that can be used to determine levels of gene expression (including protein levels), such as CC2 of the present invention, in a sample derived from a patient are well known to those of skill in the art. Such assay methods include, without limitation, radioimmunoassays, reverse transcriptase PCR (RT-PCR) assays, immunohistochemistry assays, *in situ* hybridization assays, competitive-binding assays, Western Blot analyses, ELISA assays and proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel based approaches such as mass spectrometry or protein interaction profiling. Among these, ELISAs are frequently preferred to diagnose a gene's expressed protein in biological fluids.

An ELISA assay initially comprises preparing an antibody, if not readily available from a commercial source, specific to CC2, preferably a monoclonal antibody. In addition a reporter antibody generally is prepared which binds specifically to CC2. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, for example horseradish peroxidase enzyme or alkaline phosphatase.

- 12 -

To carry out the ELISA, antibody specific to CC2 is incubated on a solid support, e.g. a polystyrene dish, that binds the antibody. Any free protein binding sites on the dish are then covered by incubating with a non-specific protein such as bovine serum albumin. Next, the sample to be analyzed is incubated in the dish, during which time CC2 binds to the specific antibody attached to the polystyrene dish. Unbound sample is washed out with buffer. A reporter antibody specifically directed to CC2 and linked to horseradish peroxidase is placed in the dish resulting in binding of the reporter antibody to any monoclonal antibody bound to CC2. Unattached reporter antibody is then washed out. Reagents for peroxidase activity, including a colorimetric substrate are then added to the dish.

15 Immobilized peroxidase, linked to CC2 antibodies, produces a colored reaction product. The amount of color developed in a given time period is proportional to the amount of CC2 protein present in the sample. Quantitative results typically are obtained by reference to a standard curve.

20 A competition assay can also be employed wherein antibodies specific to CC2 are attached to a solid support and labeled CC2 and a sample derived from the host are passed over the solid support. The amount of label detected which is attached to the solid support can be correlated to a quantity of CC2 in the sample.

Nucleic acid methods can also be used to detect CC2 mRNA as a marker for gastrointestinal cancers. Polymerase chain reaction (PCR) and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASABA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other mRNA species. In RT-PCR, an

30
35

- 13 -

mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction. RT-PCR can thus reveal by amplification the presence of a single species of mRNA. Accordingly, if the mRNA is highly specific for the cell that produces it, RT-PCR can be used to identify the presence of a specific type of cell.

Hybridization to clones or oligonucleotides arrayed on a solid support (i.e. gridding) can be used to detect both the expression of and quantitate the level of expression of a gene. In this approach, a cDNA encoding the CC2 gene is fixed to a substrate. The substrate may be of any suitable type including but not limited to glass, nitrocellulose, nylon or plastic. At least a portion of the DNA encoding the CC2 gene is attached to the substrate and then incubated with the analyte, which may be RNA or a complementary DNA (cDNA) copy of the RNA, isolated from the tissue of interest. Hybridization between the substrate bound DNA and the analyte can be detected and quantitated by several means including but not limited to radioactive labeling or fluorescence labeling of the analyte or a secondary molecule designed to detect the hybrid. Quantitation of the level of gene expression can be done by comparison of the intensity of the signal from the analyte compared with that determined from known standards. The standards can be obtained by *in vitro* transcription of the target gene, quantitating the yield, and then using that material to generate a standard curve.

Of the proteomic approaches, 2D electrophoresis is a technique well known to those in the art. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by different characteristics usually on polyacrylamide gels. First, proteins are separated by size using an electric current. The current acts uniformly on all proteins, so

- 14 -

smaller proteins move farther on the gel than larger proteins. The second dimension applies a current perpendicular to the first and separates proteins not on the basis of size but on the specific electric charge carried by each protein. Since no two proteins with different sequences are identical on the basis of both size and charge, the result of a 2D separation is a square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts (homogenates or solubilized tissue) obtained from a patient including those from tissue biopsies and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. Blood can include whole blood, plasma, serum or any derivative of blood.

In Vivo Antibody Use

Antibodies which specifically bind to CC2 can also be used *in vivo* in patients suspected of suffering from gastrointestinal cancers including stomach cancer, cancer of the small intestine, and colon cancer. Specifically, antibodies which specifically bind a CC2 can be injected into a patient suspected of having a gastrointestinal cancer for diagnostic and/or therapeutic purposes. The preparation and use of antibodies for *in vivo* diagnosis is well known in the art. For example, antibody-chelators labeled with Indium-111 have been described for use in the radioimmunoscentigraphic imaging of carcinoembryonic antigen expressing tumors (Sumerdon et al. Nucl. Med. Biol. 1990 17:247-254). In particular, these antibody-chelators have been used in detecting tumors in patients suspected of

- 15 -

having recurrent colorectal cancer (Griffin et al. J. Clin. Onc. 1991 9:631-640). Antibodies with paramagnetic ions as labels for use in magnetic resonance imaging have also been described (Lauffer, R.B. Magnetic Resonance in Medicine 5 1991 22:339-342). Antibodies directed against CC2 can be used in a similar manner. Labeled antibodies which specifically bind CC2 can be injected into patients suspected of having a gastrointestinal cancer for the purpose of diagnosing or staging of the disease status of 10 the patient. The label used will be selected in accordance with the imaging modality to be used. For example, radioactive labels such as Indium-111, Technetium-99m or Iodine-131 can be used for planar scans or single photon emission computed tomography (SPECT). Positron emitting 15 labels such as Fluorine-19 can be used in positron emission tomography. Paramagnetic ions such as Gadolinium (III) or Manganese (II) can be used in magnetic resonance imaging (MRI). Localization of the label permits determination of the spread of the cancer. The amount of label within an 20 organ or tissue also allows determination of the presence or absence of cancer in that organ or tissue.

For patients diagnosed with a gastrointestinal cancer, injection of an antibody which specifically binds CC2 can also have a therapeutic benefit. The antibody may exert 25 its therapeutic effect alone. Alternatively, the antibody may be conjugated to a cytotoxic agent such as a drug, toxin or radionuclide to enhance its therapeutic effect. Drug monoclonal antibodies have been described in the art for example by Garnett and Baldwin, Cancer Research 1986 30 46:2407-2412. The use of toxins conjugated to monoclonal antibodies for the therapy of various cancers has also been described by Pastan et al. Cell 1986 47:641-648. Yttrium-90 labeled monoclonal antibodies have been described for maximization of dose delivered to the tumor while limiting 35 toxicity to normal tissues (Goodwin and Meares Cancer

- 16 -

Supplement 1997 80:2675-2680). Other cytotoxic radionuclides including, but not limited to Copper-67, Iodine-131 and Rhenium-186 can also be used for labeling of antibodies against CC2.

5 Antibodies which can be used in these *in vivo* methods include polyclonal, monoclonal and omniclonal antibodies and antibodies prepared via molecular biology techniques. Antibody fragments and aptamers and single-stranded
10 oligonucleotides such as those derived from an *in vitro* evolution protocol referred to as SELEX and well known to those skilled in the art can also be used.

 The present invention is further described by the following examples. These examples are provided solely to illustrate the invention by reference to specific
15 embodiments. These exemplifications, while illustrating certain aspects of the invention, do not portray the limitations or circumscribe the scope of the disclosed invention.

EXAMPLES

20 The examples were carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. Routine molecular biology techniques of the following example can be carried out as described in
25 standard laboratory manuals, such as Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989).

 Real-Time quantitative PCR with fluorescent Taqman
30 probes is a quantitation detection system utilizing the 5'-3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream 3' quencher dye. During PCR, the 5'-3' nuclease activity of

- 17 -

Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA).

5 Amplification of an endogenous control was used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or 18S ribosomal RNA (rRNA) was used
10 as this endogenous control. To calculate relative quantitation between all the samples studied, the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the calibrator is obtained using the standard curve method
15 or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

To evaluate the tissue distribution, and the level of CC2 in normal and tumor tissue, total RNA was extracted from normal tissues, tumor tissues, and from tumors and the
20 corresponding matched normal tissues. Subsequently, first strand cDNA was prepared with reverse transcriptase and the polymerase chain reaction was done using primers and Taqman probe specific to CC2. The results were analyzed using the ABI PRISM 7700 Sequence Detector and are provided in the
25 following table. The absolute numbers are relative levels of expression of CC2 compared to the kidney (calibrator).

The absolute numbers depicted in Table 1 are relative levels of expression of CC2 in 12 normal different tissues. All the values are compared to normal kidney (calibrator).
30 These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

- 18 -

Table 1: Relative Levels of CC2 Expression in Pooled Samples

| Tissue | NORMAL |
|-----------------|---------------|
| Colon-Ascending | 536 |
| Endometrium | 0 |
| Kidney | 1 |
| Liver | 10 |
| Ovary | 4 |
| Pancreas | 22 |
| Prostate | 332 |
| Small Intestine | 2539 |
| Spleen | 0.0 |
| Stomach | 2062 |
| Testis | 112 |
| Uterus | 2 |

The relative levels of expression in Table 1 show that the higher level of expression of CC2 mRNA is in tissues from the gastrointestinal tract, small intestine (2539), stomach (2062), and colon (536), with a lower level of expression in prostate (332), and testis (112). These results establish that CC2 mRNA expression is highly specific for gastrointestinal tissues including not only the colon but also the small intestine and stomach.

The absolute numbers in Table 1 were obtained analyzing pools of samples of a particular tissue from different individuals. They should not be compared to the absolute numbers originated from RNA obtained from tissue samples of single individuals depicted in Table 2.

The absolute numbers depicted in Table 2 are relative levels of expression of CC2 in 78 pairs of matching samples. All the values are compared to normal kidney (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Table 2: Relative Levels of CC2 Expression in Pooled Samples

| | Sample ID | Tissue | Cancer Tissue | Normal Adjacent Tissue |
|----|-----------|-------------------|---------------|------------------------|
| | StoAC93 | Stomach 1 | 64860 | 279026 |
| 5 | Sto728 | Stomach 2 | 0 | 40 |
| | Sto758S | Stomach 3 | 21029 | 2903 |
| | Sto915S | Stomach 4 | 3488 | 56 |
| | StoAC99 | Stomach 5 | 1162 | 330 |
| | Sto115S | Stomach 6 | 404 | 146 |
| 10 | Sto15S | Stomach 7 | 4636 | 14 |
| | Sto17S | Stomach 8 | 59662 | 538 |
| | Sto261S | Stomach 9 | 53061 | 8977 |
| | Sto264S | Stomach 10 | 27492 | 84643 |
| | Sto27S | Stomach 11 | 20784 | 61 |
| 15 | Sto288S | Stomach 12 | 0 | 67 |
| | Sto531S | Stomach 13 | 53192 | 8847 |
| | Sto539S | Stomach 14 | 1492 | 27 |
| | Sto542S | Stomach 15 | 26382 | 425 |
| | Sto610S | Stomach 16 | 1029 | 20 |
| 20 | Sto88S | Stomach 17 | 3846 | 12 |
| | StoAc44 | Stomach 18 | 1.7 | 78 |
| | StoMT54 | Stomach 19 | 971 | 67 |
| | StoTA73 | Stomach 20 | 35653 | 6020 |
| | SmI21XA | Small Intestine 1 | 31016 | 10022 |
| 25 | SmIH89 | Small Intestine 2 | 645 | 2227 |
| | ClnB56 | Colon-Cecum 1 | 6816 | 971 |
| | ClnAS45 | Colon-Ascending 2 | 8757 | 5501 |
| | ClnCM67 | Colon-Cecum 3 | 2394 | 578 |
| | ClnAS67 | Colon-Ascending 4 | 1566 | 1198 |

- 20 -

| | | | | |
|----|----------|-----------------------------|--------|--------|
| | ClnAS43 | Colon-Ascending 5 | 127934 | 923 |
| | ClnAS46 | Colon-Ascending 6 | 96620 | 3316 |
| | ClnAS98 | Colon Ascending 7 | 83822 | 392 |
| | ClnAS89 | Colon-Ascending 8 | 10231 | 4 |
| 5 | ClnTX01 | Colon-Transverse 9 | 92 | 331 |
| | ClnTX89 | Colon-Transverse 10 | 11114 | 17 |
| | ClnTX67 | Colon-Transverse 11 | 683 | 189 |
| | ClnMT38 | Colon-Splenic flexure 12 | 0 | 6230 |
| | ClnSG89 | Colon-Sigmoid 13 | 2557 | 1243 |
| 10 | ClnSG67 | Colon-Sigmoid 14 | 39 | 132 |
| | ClnSG33 | Colon-Sigmoid 15 | 17080 | 118542 |
| | ClnSG45 | Colon-Sigmoid 16 | 243 | 80 |
| | ClnB34 | Colon-Rectosigmoid 17 | 130 | 11 |
| | ClnCXGA | Colon-Rectum 18 | 790 | 47152 |
| 15 | ClnRC67 | Colon-Rectum 19 | 724 | 419 |
| | ClnC9XR | Colon-Rectosigmoid 20 | 425 | 113 |
| | ClnRS45 | Colon-Rectosigmoid 21 | 42202 | 1117 |
| | ClnRC01 | Colon-Rectum 22 | 2693 | 99 |
| | ClnRC89 | Colon-Rectum 23 | 0 | 2402 |
| 20 | Bld46XK | Bladder 1 | 0 | 0 |
| | Bld66X | Bladder 2 | 15 | 4 |
| | Bld32XK | Bladder 3 | 8.5 | 0.4 |
| | Kid126XD | Kidney 1 | 5 | 5 |
| | Kid12XD | Kidney 2 | 2 | 0 |
| 25 | Kid5XD | Kidney 3 | 3.7 | 0.8 |
| | Kid6XD | Kidney 4 | 4.3 | 0 |
| | Kid106XD | Kidney 5 | 0 | 0.8 |
| | Liv42X | Liver 1 | 2 | 1 |
| | Liv15XA | Liver 2 | 0.2 | 0.7 |
| 30 | Liv94XA | Liver 3 | 0 | 1.4 |

- 21 -

| | | | | |
|----|-----------|-----------------|-------|-------|
| 5 | LngAC69 | Lung 1 | 2 | 0 |
| | LngBR94 | Lung 2 | 3 | 0 |
| | Lng47XQ | Lung 3 | 0 | 0 |
| | Mam59X | Mammary Gland 1 | 0 | 0 |
| | MamB011X | Mammary Gland 2 | 0 | 0 |
| 10 | MamA06X | Mammary Gland 3 | 15 | 20 |
| | Ovr103X | Ovary 1 | 4 | 0 |
| | Ovr130X | Ovary 2 | 3 | 3 |
| | Pan71XL | Pancreas 1 | 69458 | 15147 |
| | Pan82XP | Pancreas 2 | 0 | 0 |
| 15 | Pan77X | Pancreas 3 | 0 | 0 |
| | Pan92X | Pancreas 4 | 4696 | 52 |
| | PanC044 | Pancreas 5 | 34 | 0 |
| | Pro12B | Prostate 1 | 21 | 2 |
| | Pro23B | Prostate 2 | 23 | 6 |
| 20 | Pro13XB | Prostate 3 | 6 | 23 |
| | Pro34B | Prostate 4 | 152 | 75 |
| | Pro20XB | Prostate 5 | 112 | 13 |
| | Pro65XB | Prostate 6 | 60 | 683 |
| | Tst39X | Testis 1 | 2361 | 17 |
| 25 | Endo10479 | Endometrium 1 | 32 | 0 |
| | Utr85XU | Uterus 1 | 0 | 0 |

0= Negative

In the analysis of matching samples, the higher levels of expression for CC2 are in stomach, small intestine, and colon. This pattern shows a high degree of specificity for gastrointestinal tissues including, not only the colon, but also the stomach and small intestine. These results confirm the tissue specificity results obtained with the panel of normal pooled samples (shown in Table 1).

- 22 -

The level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual were also compared. This comparison provides an indication of specificity for the cancer stage (e.g. different levels of mRNA expression in the cancer sample compared to the normal adjacent tissue). Table 2 shows overexpression of CC2 in 15 primary stomach cancer tissues compared with their respective normal adjacent (stomach samples #3, 4, 5, 6, 7, 8, 9, 11, 13, 14, 15, 16, 17, 19, and 20). There is overexpression in the cancer tissues for 75% of the stomach matching samples tested (total of 20 stomach matching samples).

CC2 is also differentially expressed in the two tested matching samples for cancer of the small intestine. Sample #1 shows upregulation for the mRNA of CC2 in cancer, whereas sample #2, shows lower expression in cancer.

CC2 is differentially expressed in twenty-three matching samples for colon cancer. Samples #1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 13, 16, 17, 19, 20, 21 and 22 show upregulation for the mRNA of CC2 in cancer, whereas samples #9, 12, 14, 15, 18, and 23 show lower expression in the cancer sample when compared to the normal adjacent tissue.

Altogether, the high level of tissue specificity for gastrointestinal tissues, plus the mRNA differential expression in several of the primary stomach, small intestine, and colon matching samples tested indicate CC2 to be a diagnostic marker for gastrointestinal cancers including not only colon cancer, but also stomach cancer and cancer of the small intestine.

- 23 -

What is claimed is:

1. A method for diagnosing the presence of a gastrointestinal cancer in a patient comprising:

- (a) measuring levels of CC2 in cells, tissues or
5 bodily fluids in a patient; and
- (b) comparing the measured levels of CC2 with levels of CC2 in cells, tissues or bodily fluids from a normal human control, wherein a change in measured levels of CC2
10 in said patient versus normal human control is associated with the presence of a gastrointestinal cancer.

2. A method of diagnosing metastases of a gastrointestinal cancer in a patient comprising:

- (a) identifying a patient having a gastrointestinal cancer that is not known to have metastasized;
- 15 (b) measuring CC2 levels in a sample of cells, tissues, or bodily fluid from said patient; and
- (c) comparing the measured CC2 levels with levels of CC2 in cells, tissue, or bodily fluid of a normal human control, wherein an increase in measured CC2 levels in the
20 patient versus the normal human control is associated with a cancer which has metastasized.

3. A method of staging a gastrointestinal cancer in a patient having a gastrointestinal cancer comprising:

- (a) identifying a patient having a gastrointestinal
25 cancer;
- (b) measuring CC2 levels in a sample of cells, tissue, or bodily fluid from said patient; and
- (c) comparing measured CC2 levels with levels of CC2 in cells, tissues, or bodily fluid of a normal human
30 control, wherein an increase in measured CC2 levels in said patient versus the normal human control is associated with a cancer which is progressing and a decrease in the

- 24 -

measured CC2 levels is associated with a cancer which is regressing or in remission.

4. A method of monitoring a gastrointestinal cancer in a patient for the onset of metastasis comprising:

- 5 (a) identifying a patient having a gastrointestinal cancer that is not known to have metastasized;
- (b) periodically measuring levels of CC2 in samples of cells, tissues, or bodily fluid from said patient; and
- (c) comparing the periodically measured CC2 levels
10 with levels of CC2 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CC2 levels in the patient versus the normal human control is associated with a cancer which has metastasized.

15 5. A method of monitoring a change in stage of a gastrointestinal cancer in a patient comprising:

- (a) identifying a patient having a gastrointestinal cancer;
- (b) periodically measuring levels of CC2 in cells,
20 tissues, or bodily fluid from said patient; and
- (c) comparing the periodically measured CC2 levels with levels of CC2 in cells, tissues, or bodily fluid of a normal human control, wherein an increase in any one of the periodically measured CC2 levels in the patient versus the
25 normal human control is associated with a cancer which is progressing in stage and a decrease is associated with a cancer which is regressing in stage or in remission.

6. The method of claim 1, 2, 3, 4 or 5 wherein the CC2 comprises SEQ ID NO:1 or SEQ ID NO:2.

30 7. An antibody which specifically binds CC2.

- 25 -

8. A method of imaging a gastrointestinal cancer in a patient comprising administering to the patient an antibody of claim 7.

9. The method of claim 8 wherein said antibody is
5 labeled with paramagnetic ions or a radioisotope.

10. A method of treating a gastrointestinal cancer in a patient comprising administering to the patient an antibody of claim 7.

11. The method of claim 10 wherein the antibody is
10 conjugated to a cytotoxic agent.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|---|
| (51) International Patent Classification ⁶: C12Q 1/68, G01N 33/53, C07K 16/00, 16/18, 16/30 | A1 | (11) International Publication Number: WO 00/20640 (43) International Publication Date: 13 April 2000 (13.04.00) |
| (21) International Application Number: PCT/US99/22725 (22) International Filing Date: 30 September 1999 (30.09.99) (30) Priority Data: 60/102,879 2 October 1998 (02.10.98) US (71) Applicant (for all designated States except US): DIADEXUS LLC [US/US]; 3303 Octavius Drive, Santa Clara, CA 95054 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): MACINA, Roberto, A. [AR/US]; 4118 Crescendo Avenue, San Jose, CA 95136 (US). (74) Agents: LICATA, Jane, Massey et al.; Law Offices of Jane Massey Licata, 66 E. Main Street, Marlton, NJ 08053 (US). | | (81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> |
| (54) Title: A NOVEL METHOD OF DIAGNOSING, MONITORING, STAGING, IMAGING AND TREATING GASTROINTESTINAL CANCERS (57) Abstract The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating gastrointestinal cancers including small intestine, colon and stomach cancer. | | |

Docket No.
DEX-0184

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A Novel Method of Diagnosing, Monitoring, Staging, Imaging and Treating Gastrointestinal Cancers

the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 30 September 1999 as United States Application No. or PCT International Application Number PCT/US9922725 and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

| | |
|-----------------------------------|------------------------|
| 60/102,879 | 2 October 1998 |
| _____ (Application Serial No.) | _____ (Filing Date) |
| _____ (Application Serial No.) | _____ (Filing Date) |
| _____ (Application Serial No.) | _____ (Filing Date) |

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

| | | |
|-----------------------------------|------------------------|---|
| _____ (Application Serial No.) | _____ (Filing Date) | _____ (Status) (patented, pending, abandoned) |
| _____ (Application Serial No.) | _____ (Filing Date) | _____ (Status) (patented, pending, abandoned) |
| _____ (Application Serial No.) | _____ (Filing Date) | _____ (Status) (patented, pending, abandoned) |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*



26259

PATENT TRADEMARK OFFICE

Send Correspondence to: Jane Massey Licata or Kathleen A. Tyrrell
Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata or Kathleen A. Tyrrell - (856) 810-1515

| | |
|---|------------------------|
| Full name of sole or first inventor Roberto A. Macina | Date 6/27/01 |
| Sole or first inventor's signature <i>[Signature]</i> | |
| Residence San Jose, California <i>CA</i> | |
| Citizenship Argentina | |
| Post Office Address 4118 Crescendo Avenue | |
| San Jose, California 95054 | |

| | |
|--------------------------------------|------|
| Full name of second inventor, if any | |
| Second inventor's signature | Date |
| Residence | |
| Citizenship | |
| Post Office Address | |
| | |

SEQUENCE LISTING

<110> Macina, Roberto A.
DIADEXUS LLC

<120> A Novel Method of Diagnosing, Monitoring, Staging,
Imaging and Treating Gastrointestinal Cancers

<130> DEX-0047

<140>

<141>

<150> 60/102,879

<151> 1998-10-02

<160> 2

<170> PatentIn Ver. 2.0

<210> 1

<211> 1255

<212> DNA

<213> Homo sapiens

<220>

<221> unsure

<222> (1224)

<220>

<221> unsure

<222> (1234)

<220>

<221> unsure

<222> (1238)

<220>

<221> unsure

<222> (1247) .. (1248)

<400> 1

```
aagatataaa agctccagaa acgttgactg ggaccactgg aggcacgagg aaggcagggg 60
cccttagagt cttggttgcc aaacagattt gcagatcaag gagaaccag gagtttcaaa 120
gaagcgctag taaggtctct gagatccttg cactagctac atcctcaggg taggaggaag 180
atgggttcca gaagcatgcg gctgctccta ttgctgagct gcctggccaa aacaggagtc 240
ctgggtgata tcatcatgag accagctgt gctcctggat ggttttacca caagtccaat 300
tgctatggtt acttcaggaa gctgaggaac tggctctgat ccgagctcga gtgtcagtct 360
```

tacggaaaacg gagcccacct ggcattctatc ctgagtttaa aggaagccag caccatagca 420
 gagtacataa gtggctatca gagaagccag ccgatatgga ttggcctgca cgacccacag 480
 aagaggcagc agtggcagtg gattgatggg gccatgtatc tgtacagatc ctgggtctggc 540
 aagtccatgg gtgggaacaa gcaactgtgt gagatgagct ccaataacaa ctttttaact 600
 tggagcagca acgaatgcaa caagcgccaa cacttcctgt gcaagtaccg accatagagc 660
 aagaatcaag attctgctaa ctctgcaca gcccgcctc cttcctttct gctagcctgg 720
 ctaaactctgc tcattatttc agaggggaaa cctagcaaac taagagtgat aagggcccta 780
 ctacactggc ttttttaggc ttagagacag aaactttagc attggcccag tagtggttc 840
 tagctctaaa tgtttgcccc gccatccctt tccacagtat cttcttccc tcctcccctg 900
 tctctggctg tctcgagcag tctagaagag tgcattctca gcctatgaaa cagctgggtc 960
 tttggccata agaagtaaag atttgaagac agaaggaaga aactcaggag taagcttcta 1020
 gaccccttca gcttctacac cttctgccc tctctccatt gcctgcaccc caccacagcc 1080
 actcaactcc tgcttgtttt tcctttggcc ataggaaggt ttaccagtag aatccttgct 1140
 aggttgatgt gggccataca ttcctttaat aaaccattgt gtacatgaag aaaaaaaaaa 1200
 aaaaaaaaaa aaaggggggg ccgnttcaag gggntccnaa gtttganntg acggg 1255

<210> 2

<211> 153

<212> PRT

<213> Homo sapiens

<400> 2

Met Arg Leu Leu Leu Leu Leu Ser Cys Leu Ala Lys Thr Gly Val Leu
 1 5 10 15
 Gly Asp Ile Ile Met Arg Pro Ser Cys Ala Pro Gly Trp Phe Tyr His
 20 25 30
 Lys Ser Asn Cys Tyr Gly Tyr Phe Arg Lys Leu Arg Asn Trp Ser Asp
 35 40 45
 Ala Glu Leu Glu Cys Gln Ser Tyr Gly Asn Gly Ala His Leu Ala Ser
 50 55 60
 Ile Leu Ser Leu Lys Glu Ala Ser Thr Ile Ala Glu Tyr Ile Ser Gly
 65 70 75 80
 Tyr Gln Arg Ser Gln Pro Ile Trp Ile Gly Leu His Asp Pro Gln Lys
 85 90 95
 Arg Gln Gln Trp Gln Trp Ile Asp Gly Ala Met Tyr Leu Tyr Arg Ser
 100 105 110
 Trp Ser Gly Lys Ser Met Gly Gly Asn Lys His Cys Ala Glu Met Ser
 115 120 125
 Ser Asn Asn Asn Phe Leu Thr Trp Ser Ser Asn Glu Cys Asn Lys Arg
 130 135 140

WO 00/20640

PCT/US99/22725

Gln His Phe Leu Cys Lys Tyr Arg Pro
145 150